Why Does Insulin Cost So Much? Big Pharma Isn鈥檛 the Only Player Driving Prices
Big Pharma may be moving on from squeezing diabetes patients on insulin prices, but it鈥檚 the arbitrators that jack up prices for those who can least afford them.
Drugs
281 - 300 of 1,297 Results
-
-
Watch: Walgreens Won’t Sell Abortion Pill in 21 States Under GOP Threat of Legal Action
Under pressure from Republican attorneys general, the nation's second-largest pharmacy chain says it will not dispense the abortion pill mifepristone.
By Sarah Varney -
Despite Pharma Claims, Illicit Drug Shipments to US Aren鈥檛 Full of Opioids. It鈥檚 Generic Viagra.
The FDA has long blocked the importation of cheap medicine, agreeing with pharmaceutical manufacturers that it opens the door to opioids. The agency鈥檚 own data shows that rarely happens.
-
Journalists Discuss Insulin Prices, Gun Violence, Distracted Driving, and More
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
March Medicaid Madness
Episode 287President Joe Biden and Republicans in Congress spent last month sparring over whether to shield Medicare and Social Security from budget cuts 鈥 leading some to wonder if Medicaid was on the table instead. Biden and Democrats say no, but some Republicans seem eager to trim federal spending on the health program for Americans with low incomes. And ready or not, artificial intelligence is coming to medical care. Benefits, as well as unintended consequences, are likely. Alice Miranda Ollstein of Politico, Rachel Cohrs of STAT News, and Lauren Weber of The Washington Post join KHN鈥檚 chief Washington correspondent, Julie Rovner, to discuss these issues and more.
-
Eli Lilly Slashed Insulin Prices. This Starts a Race to the Bottom.
Eli Lilly's news that it plans to cut insulin costs for patients will help, not hinder, the recent efforts in California and by entrepreneurs such as Mark Cuban to offer lower-cost alternatives, drug pricing experts said.
By Bram Sable-Smith and Samantha Young -
Readers and Tweeters Urgently Plea for a Proper ‘Role’ Call in the ER
KHN gives readers a chance to comment on a recent batch of stories.
-
After Capping Insulin Copays, Colorado Sets Its Sights on EpiPens
Colorado鈥檚 proposed legislation to cap the copay for the EpiPen is part of a nationwide trend as more states try to shield patients from skyrocketing drug prices.
-
One Texas Judge Will Decide Fate of Abortion Pill Used by Millions of American Women
鈥淲hat happens in Texas doesn't stay in Texas,鈥 warns an abortion rights advocate bracing for a district judge鈥檚 ruling on whether the abortion pill mifepristone was properly authorized by the FDA. His decision could force the medication off the U.S. market.
By Sarah Varney -
A Bitter Battle Over the 鈥極rphan Drug鈥 Program Leaves Patients鈥 Pocketbooks at Risk
Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.
-
Mark Cuban Has Been Taking On the Drug Industry. But Which One?
The billionaire entrepreneur and NBA team owner is making waves with his new drug company. But his generics aren鈥檛 always the lowest-priced deal.
By Darius Tahir The Kids Are Not OK
Episode 285A new survey from the Centers for Disease Control and Prevention finds that teenagers, particularly girls, are reporting all-time high rates of violence and profound mental distress. Meanwhile, both sides in the abortion debate are anxiously waiting for a district court decision in Texas that could effectively revoke the FDA鈥檚 22-year-old approval of the abortion pill mifepristone. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN鈥檚 chief Washington correspondent, Julie Rovner, to discuss these issues and more.
-
Postcard From a Philadelphia Neighborhood
As Opioids Mixed With Animal Tranquilizers Arrive in Kensington, So Do Alarming Health Challenges
The veterinary tranquilizer xylazine, the choice du jour of local drug dealers to cut fentanyl, leads to necrotic ulcers and leaves street medics and physicians confused about how best to deal with this wave of the opioid crisis.
-
Armed With Hashtags, These Activists Made Insulin Prices a Presidential Talking Point
Twitter has been a hotbed for the burgeoning insulin access movement and activism surrounding other medical conditions. For people with diabetes, the platform has helped propel concern about insulin prices into policy. Can it continue to win with hashtags?
-
Your Money or Your Life: Patient on $50,000-a-Week Cancer Drug Fears Leaving Behind Huge Medical Debt
When Medicare stops paying for a pricey drug that prolongs life, an Ohio man considers giving up treatment to spare his family enormous debt.
By Fred Schulte -
Era of 鈥楩ree鈥 Covid Vaccines, Test Kits, and Treatments Is Ending. Who Will Pay the Tab Now?
Insurers, employers, and taxpayers will all be affected as drug manufacturers move these products to the commercial market.
A Health-Heavy State of the Union
Episode 284President Joe Biden鈥檚 2023 State of the Union address leaned heavily on health care issues. Biden took a victory lap for recent accomplishments like capping prescription drug costs for seniors on Medicare. He also urged Congress to make permanent the boosted premium subsidies under the Affordable Care Act, and he sparred with Republicans on threats to cut Social Security and Medicare. Also this week, both sides in the abortion debate are bracing for a court decision out of Texas that could, at least temporarily, make the abortion pill mifepristone illegal nationwide. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Kate Baicker of the University of Chicago about a possible middle ground in the effort to get universal health insurance coverage.
-
Centene Agrees to $215 Million Settlement With California for Alleged Medicaid Overbilling
The nation鈥檚 largest Medicaid insurer denies wrongdoing after the California attorney general鈥檚 office investigated it for inflating prescription drug costs.
-
鈥榃e Ain鈥檛 Gonna Get It鈥: Why Bernie Sanders Says His ‘Medicare for All’ Dream Must Wait
As he takes the reins of the Senate Health, Education, Labor & Pensions Committee, the independent from Vermont and implacable champion of 鈥淢edicare for All鈥 maps out his strategy for negotiating with Republicans 鈥 and Big Pharma.
By Arthur Allen -
The Pill Club Reaches $18.3 Million Medicaid Fraud Settlement With California
The online women鈥檚 pharmacy agreed to pay $15 million to the state Department of Justice and $3.3 million to the Department of Insurance over claims it overbilled Medi-Cal.
By Don Thompson